Oxymorphone ER

DRUG6 trials

Sponsors

Endo Pharmaceuticals, MedVadis Research Corporation, Icahn School of Medicine at Mount Sinai

Conditions

Cancers, PainChronic Nociceptive PainChronic PainHealthyLower Back PainNeuropathic PainNon-cancer PainPain

Phase 3

Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects

TerminatedNCT00765856

Endo PharmaceuticalsChronic Pain

Start: 2008-11-17End: 2010-02-22Updated: 2020-12-16

Open Label Assessment of Long-Term Safety and Utility

CompletedNCT00904449

Endo PharmaceuticalsPain

Start: 2001-04-30End: 2002-12-31Updated: 2010-02-10

Open-Label Extension to Evaluate the Long-Term Safety, Tolerability and Analgesic Efficacy

CompletedNCT00904280

Endo PharmaceuticalsCancers, Pain, Lower Back Pain

Start: 2001-03-31End: 2003-07-31Updated: 2009-05-19

Phase 4

Effect of Extended-release Oxymorphone Taken With or Without Food on Cognitive Functioning

CompletedNCT00930943

MedVadis Research CorporationChronic Pain

Start: 2009-05-31End: 2009-11-30Updated: 2023-05-09

Study to Compare Oxymorphone Extended-Release (Opana ER) Versus Oxycodone Controlled-Release (Oxycontin)

CompletedNCT00955110

Endo PharmaceuticalsHealthy

Start: 2009-06-30End: 2009-09-30Updated: 2017-10-05

Unknown Phase

A Pilot Study of Ultra Rapid Opioid Rotation and Titration of Oxymorphone

Icahn School of Medicine at Mount SinaiChronic Nociceptive Pain, Neuropathic Pain, Non-cancer Pain

Start: 2009-07-31End: 2011-05-31Target: 12Updated: 2009-07-24